IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Purchased by MJP Associates Inc. ADV

MJP Associates Inc. ADV increased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 31.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 953 shares of the company’s stock after acquiring an additional 230 shares during the quarter. MJP Associates Inc. ADV’s holdings in IDEXX Laboratories were worth $515,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Valley National Advisers Inc. boosted its position in IDEXX Laboratories by 84.6% during the fourth quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock worth $26,000 after acquiring an additional 22 shares during the last quarter. Geo Capital Gestora de Recursos Ltd acquired a new position in IDEXX Laboratories during the third quarter worth about $28,000. Covestor Ltd boosted its position in IDEXX Laboratories by 71.8% during the third quarter. Covestor Ltd now owns 67 shares of the company’s stock worth $29,000 after acquiring an additional 28 shares during the last quarter. DSM Capital Partners LLC acquired a new position in IDEXX Laboratories during the fourth quarter worth about $33,000. Finally, Venturi Wealth Management LLC boosted its position in IDEXX Laboratories by 226.3% during the fourth quarter. Venturi Wealth Management LLC now owns 62 shares of the company’s stock worth $34,000 after acquiring an additional 43 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director Bruce L. Claflin sold 200 shares of the business’s stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $540.80, for a total transaction of $108,160.00. Following the completion of the transaction, the director now owns 161 shares in the company, valued at approximately $87,068.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 2.11% of the stock is currently owned by company insiders.

IDEXX Laboratories Trading Down 0.0 %

Shares of IDEXX Laboratories stock traded down $0.23 on Friday, reaching $495.73. The company had a trading volume of 1,220,027 shares, compared to its average volume of 464,496. The firm’s 50 day moving average price is $500.80 and its two-hundred day moving average price is $528.24. The firm has a market cap of $40.94 billion, a PE ratio of 47.99, a PEG ratio of 4.05 and a beta of 1.33. IDEXX Laboratories, Inc. has a 52-week low of $372.50 and a 52-week high of $583.39. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.16 and a current ratio of 1.57.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Wednesday, May 1st. The company reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.13. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. The firm had revenue of $964.10 million for the quarter, compared to the consensus estimate of $965.43 million. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

IDXX has been the topic of a number of recent research reports. Barclays lowered their price target on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a research report on Thursday, May 2nd. StockNews.com raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, June 14th. Morgan Stanley reduced their target price on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 14th. Finally, William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $580.38.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.